CELL INTELLIGENCE · 肿瘤细胞治疗研究

儿童脑肿瘤的局部区域和全身过继性细胞疗法：CAR-T、TCR 工程 T 细胞和 NK 细胞策略的系统综述

Locoregional and systemic adoptive cellular therapies for pediatric brain tumors: a systematic review of CAR‑T, TCR‑engineered T cells, and NK cell st

伊布替尼联合曲妥珠单抗治疗 HER2 阳性转移性乳腺癌的 I/II 期研究

A Phase I/II Study of Ibrutinib Plus Trastuzumab in HER2-Positive Metastatic Breast Cancer.

肉瘤细胞治疗的演变：突破、挑战与未来方向

The evolution of cellular therapies in sarcoma: Breakthroughs, challenges, and future directions.

嵌合抗原受体自然杀伤（CAR-NK）细胞治疗乳腺癌的疗效与安全性评价：系统综述与荟萃分析

Evaluation of Efficacy and Safety of Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cells in Breast Cancer: A Systematic Review and Meta-Analysis.

转移性 HER2⁺ 乳腺癌患者中循环 miR-19a-3p 高水平与良好预后和抗肿瘤免疫应答相关

High levels of circulating miR-19a-3p in patients with metastatic HER2 + breast cancer are associated with a favorable prognosis and anti-tumor immune

CliCAR：一种非基因 CAR 工程策略，赋能 NK 细胞用于靶向癌症免疫治疗

CliCAR: A non-genetic CAR engineering strategy to empower NK cells for targeted cancer immunotherapy.

利用脐血 CD34⁺ HSPC 来源的间皮素特异性 CAR-NKT 细胞靶向三阴性乳腺癌，具有强效抗肿瘤活性

Targeting triple-negative breast cancer using cord-blood CD34⁺ HSPC-derived mesothelin-specific CAR-NKT cells with potent antitumor activity.

这些结果支持 Allo15 MCAR-NKT 细胞作为一种下一代、现成的免疫疗法，对 TNBC 具有强大的治疗潜力，特别是在转移、免疫逃逸和治疗耐药的情况下。

溶瘤腺病毒免疫治疗增强同种异体过继 HER2.CAR-NK 抗胰腺导管腺癌功能

Oncolytic adeno-immunotherapy improves allogeneic adoptive HER2.CAR-NK function against pancreatic ductal adenocarcinoma.

NK 细胞在 HER2(-) 和 HER2(+) 人乳腺癌中占据独特的空间邻域

Natural killer cells occupy unique spatial neighborhoods in HER2(-) and HER2(+) human breast cancers.

Cinrebafusp Alfa，一种 HER2/4-1BB 双特异性分子，在 HER2 阳性晚期实体恶性肿瘤患者中的首次人体研究

A First-in-Human Study of Cinrebafusp Alfa, a HER2/4-1BB Bispecific Molecule, in Patients with HER2-Positive Advanced Solid Malignancies.

Cinrebafusp alfa 在既往接受过 HER2 靶向方案后进展的 HER2 阳性恶性肿瘤患者中显示出有前景的活性。其可接受的安全性特征表明，它可能成为对现有 HER2 导向治疗无应答患者的一种治疗选择。参见 Eguren-Santamaría 等人的相关评论，第 231 页。